Manufacturing phase: From the patient's blood collected at the leukapheresis, the investigators will make the IMA201 TCR-engineered T cells. In order to insert the new gene into the patient's T-cells, investigators will use a gene transfer technology. This will be done with a lentiviral vector derived from a virus. The vector was made specifically for this study and will carry the TCR genes into the T cells.